Croatian gastric juice, a 15-amino-acid fragment, and the most popular peptide on the internet that probably never gets FDA approval.

A guy walks into a clinic with a torn rotator cuff, six months of physical therapy behind him, two cortisone shots, and an orthopedic surgeon's note recommending arthroscopic repair. He doesn't want surgery. He wants to know if BPC-157 is real.

This is now a routine conversation in regenerative medicine. The peptide has escaped containment. It started as a Croatian research project in 1993. It is currently the most-discussed peptide on Reddit. It got banned by WADA in 2022, restricted by the FDA in 2023, and as of April 2026 it is no longer on the Category 2 list because the original nominators withdrew their petitions. The PCAC reviews it again on July 23, 2026. Nobody knows where it lands.

Meanwhile the anecdotes keep coming. So does the science. So does the confusion.

Here's what's actually known.

Where it came from

BPC-157 stands for Body Protection Compound, fragment 157. It is a 15-amino-acid sequence isolated from a larger protein in human gastric juice. Predrag Sikiric and his lab at the University of Zagreb identified it in the early 1990s and have been publishing on it ever since.

GEPPPGKPADDAGLV

Most of the foundational animal data comes out of that one Croatian research group. Some collaborators in Japan, the US, and Eastern Europe have replicated pieces.

This is one of the weird things about BPC-157. It's a one-lab phenomenon. Imagine if every major paper on aspirin came from the same building in Zagreb. That's roughly the situation. It doesn't mean the data is wrong. It means the replication problem is real.

The mechanism story is also unusual. Most peptides have a clean lock-and-key explanation. BPC-157 doesn't.

The published data implicates at least five major pathways:

Angiogenesis — new blood vessel formation via VEGFR2 upregulation, accelerating tissue repair at the vascular level
Nitric oxide system modulation — counteracts both L-NAME (NO blockade) and L-arginine (NO excess), suggesting a bidirectional regulatory effect
Growth hormone receptor expression — upregulation in tendon fibroblasts, enhancing the local healing cascade
FAK-paxillin signaling — promotes cell migration and adhesion at injury sites
Gut-brain axis — dopamine and serotonin system effects, particularly relevant to gastric protection and stress-related GI pathology

That's a network drug, not a receptor drug.

What the actual studies show

Animal data is voluminous. Tendons heal faster. Ligaments heal faster. Muscle transections recover with better functional outcomes. NSAID-induced gut damage gets reversed. Stress ulcers don't form.

Cerovecki et al., 2010 — Ligament healing in the rat

Medial collateral ligament transection model. BPC-157-treated rats showed significantly improved ligament healing at 14, 45, and 90 days post-injury. Biomechanical testing confirmed superior load-to-failure strength versus controls.

Journal of Orthopaedic Research, 28(9), 1155–1161. DOI: 10.1002/jor.21107

Chang et al., 2011 — Tendon healing and cell survival

Achilles tendon fibroblast model. BPC-157 accelerated tendon outgrowth, increased cell migration, and improved cell survival under oxidative stress conditions. Mechanism via FAK-paxillin signaling pathway.

Journal of Applied Physiology, 110(3), 774–780. DOI: 10.1152/japplphysiol.00945.2010

There are dozens of these. The animal evidence base is not the problem.

Human data is thin

There are essentially three published clinical reports.

<30 total patients enrolled across all published BPC-157 human clinical data

Lee and Padgett, 2021 — Intra-articular knee injection

Retrospective chart review. 17 patients at the Institute for Hormonal Balance in Orlando. Intra-articular BPC-157 injections (alone or with TB-500) for various knee pathologies. 16 reachable for follow-up. 87.5% reported pain relief. Dose: 4mg per injection. Six-month duration of benefit. Open label, no controls, retrospective.

Alternative Therapies in Health and Medicine, 27(4), 8–13. PMID: pending

Lee, Walker, and Ayadi, 2024 — Interstitial cystitis pilot

12 patients. All reported significant improvement on the Global Response Assessment Questionnaire. Cystoscopy showed resolution of detrusor inflammation in at least one patient.

Alternative Therapies in Health and Medicine, 30(10), 12–17.

Lee and Burgess, 2025 — IV infusion safety pilot

Two healthy adults, doses up to 20mg intravenous. No serious adverse events. n=2.

PMID: 40131143

That's it. That's the human evidence base. Three papers, all from one clinician in Orlando, total enrollment under thirty. Compare that to the thousands of patients in any mainstream osteoarthritis or tendinopathy trial.

The dosing question nobody can answer

Animal studies typically use 10 mcg/kg. Translated to a 70 kg human that's 700 mcg per day. Clinical convention has settled around 250-500 mcg twice daily for systemic injury, often as subcutaneous injection. Lee's intra-articular knee work used 4 mg per joint as a one-time injection. Some practitioners go higher for stubborn cases.

Route	Typical dose	Best for	Evidence level
Subcutaneous (local)	250-500 mcg 2x/day	Tendon, ligament, local injury	Anecdotal + animal
Subcutaneous (abdominal)	250-500 mcg 2x/day	Systemic repair, gut healing	Anecdotal + animal
Intra-articular	4 mg single injection	Knee pathologies	One human study (n=17)
Oral	250-500 mcg/day	GI indications	Animal data only
IV infusion	Up to 20 mg	Research / safety	n=2 pilot

The dose-response curve in humans has not been mapped.

Oral BPC-157 is its own controversy. The molecule is unusually stable in gastric acid (this is, after all, where it was isolated from). Sikiric's group has published animal data showing oral administration produces measurable effects, particularly on the gut. Whether the same dose works as well orally as subcutaneously in humans is unknown. The pharmacology argues yes for gut indications and probably no for distant tissue repair.

Inject local or systemic? The eternal forum war

Half the internet says inject right next to the injury. The other half says it doesn't matter because once absorbed it circulates systemically. Both can be partially right.

The pharmacokinetic argument: subcutaneous BPC-157 hits the bloodstream within minutes. From there it distributes everywhere. Local injection near a tendon does give a brief tissue concentration spike before equilibrium, which could matter if the peptide has high local first-pass uptake by injured tissue (plausible but unproven in humans).

The clinical observation: patients report results from belly fat injections and from injections near the injury. The mean effect from local injection appears slightly larger in unstructured anecdotal data, which is exactly what you'd expect from a compound with any tissue avidity at all. It is not magic. The needle near the elbow is not delivering the peptide via some private courier service.

Practical answer: Subcutaneous near the injury when feasible, abdominal SQ when not, and stop catastrophizing the difference.

The regulatory soap opera

2022 WADA adds BPC-157 to the S0 prohibited list (non-approved substances). All competitive athletes under WADA jurisdiction can no longer use it.
2023 FDA places BPC-157 acetate on the Category 2 list of bulk drug substances, effectively ending legal compounding pharmacy access.
February 27, 2026 HHS Secretary Kennedy announces on the Joe Rogan Experience that approximately 14 of the 19 restricted peptides will return to Category 1.
April 22, 2026 FDA updates its bulk drug substances document. BPC-157 is removed from Category 2, but only because the nominators withdrew.
July 23, 2026 FDA consults the Pharmacy Compounding Advisory Committee about including BPC-157 acetate and BPC-157 free base on the 503A approved bulks list. This is where everything stands right now.

BPC-157 is not on the prohibited Category 2 list anymore. It is also not yet on the approved Category 1 list. It sits in administrative purgatory until the July PCAC meeting decides whether to formally bless it for compounding.

The functional reality: licensed compounding pharmacies are still hesitant to touch it pre-PCAC. Most clinicians prescribing it are working around the gap. The market for research-chemical-grade material online has not slowed.

Why it probably never gets a New Drug Application

Here is the boring economic truth about BPC-157.

Patent protection on the original BPC peptide compositions traces back to filings in the 1990s. Some of those patents are expired. Others run out within the next decade. A New Drug Application costs somewhere between 500 million and 2 billion dollars when you account for full Phase 1/2/3 trials, manufacturing scale-up, and FDA review. No pharmaceutical company will spend that money on a compound where generic competitors can copy it the day after approval.

This is the actual reason BPC-157 will probably never appear on a CVS shelf with a black-and-white prescription bottle. Not because it doesn't work. Because the patent runway is too short for the trial costs to pencil out.

The same economics keep dozens of generic-eligible compounds permanently parked in the gray market.

The PCAC review is therefore the most important pathway it has. Category 1 inclusion would let 503A and 503B compounding pharmacies make it legally with a physician's prescription. That's not FDA approval. It is regulated access. It is the compromise this category of compound was designed for.

What this means for the patient sitting in the exam room

The honest version, which is the version that actually helps people:

The animal data on tendon, ligament, muscle, and gut healing is consistent enough to be interesting. The human data is thin and from one clinic. The mechanism is genuinely novel and probably involves angiogenesis and growth factor modulation rather than direct receptor agonism. The safety profile in published work looks favorable, with the giant caveat that thirty enrolled patients across three papers is not a safety database.

Most physicians who have used BPC-157 in clinical practice report that some patients seem to respond dramatically and others not at all. Tendinopathy and gastric mucosal indications appear to be the most consistent winners. Joint pain results are variable. Acute soft tissue injuries respond better than chronic degenerative ones.

If you're considering it, three things matter more than dose or injection site.

Source. Research-chemical-grade peptides from internet vendors have well-documented quality problems. A 2023 FDA analysis found over 40% of peptide products sold through unregulated channels contained inaccurate dosing, contamination, or degraded active compound. Wait for compounding pharmacy access if you can.

WADA. The ban is real. If you compete in any sport at any level under USADA, NCAA, NFL, MLB, UFC, or any WADA-affiliated body, BPC-157 will end your season. The detection window in urine is at least 72 hours and probably longer with modern mass spectrometry.

Expectations. Do not confuse decades of animal data with proof of human efficacy. The peptide may be exactly as good as Reddit claims. It may also be 30% as good as Reddit claims. The clinical trials that would tell us are the ones nobody has commercial incentive to run.

That gap is the BPC-157 story in one sentence.

References

Cerovecki, T., Bojanic, I., Brcic, L., Radic, B., Vukoja, I., Seiwerth, S., & Sikiric, P. (2010). Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research, 28(9), 1155–1161. doi:10.1002/jor.21107
Chang, C. H., Tsai, W. C., Lin, M. S., Hsu, Y. H., & Pang, J. H. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780. doi:10.1152/japplphysiol.00945.2010
DeFoor, M. T., Dekker, T. J., Guerrero, E. M., Kuhn, A. W., & Adams, A. C. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal injuries. PMC. PMC12446177
Józwiak, M., Bauer, M., Kamysz, W., & Kleczkowska, P. (2025). Multifunctionality and possible medical application of the BPC 157 peptide: Literature and patent review. Pharmaceuticals, 18(2), 185. doi:10.3390/ph18020185
Lee, E., & Burgess, K. (2025). Safety of intravenous infusion of BPC 157 in humans: A pilot study. Alternative Therapies in Health and Medicine. PMID: 40131143
Lee, E., & Padgett, B. (2021). Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 27(4), 8–13.
Lee, E., Walker, C., & Ayadi, B. (2024). Effect of BPC-157 on symptoms in patients with interstitial cystitis: A pilot study. Alternative Therapies in Health and Medicine, 30(10), 12–17.
Sikiric, P., Seiwerth, S., Rucman, R., et al. (2014). Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 20(7), 1126–1135. doi:10.2174/1381612811319990414
U.S. Food and Drug Administration. (2026, April 22). Bulk drug substances nominated for use in compounding under section 503A: Updated list. fda.gov
World Anti-Doping Agency. (2022). World Anti-Doping Code International Standard Prohibited List 2022.

This article is for research and educational purposes only. It is not medical advice. All clinical applications referenced are conducted under IRB PPRN-001-2025 through Mortensen Medical. Consult a licensed healthcare provider before making any treatment decisions.

BPC-157: